Antibody drug conjugates (ADCs) and targeted toxins (TT) both consists of an antibody or antibody fragment linked to a cytotoxic component. These drugs are supposed to be more cancer specific with limited general toxicity as compared to conventional chemotherapy. However, unexpected toxicity and variable therapeutic outcome is experienced. Our aim in this project is to provide better predictive biomarkers for these drugs.
The project was admitted to SPARK Norway February 2021 with formal start 1 April 2021.
The project is provided an innovation grant from Helse Sør-Øst 2019.